RxBlog

Sponsor Media

Pages

RxBlog Resources

RxBlog Blogroll

  • Pfizer
    Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment.
  • Schering-Plough
    We aspire to earn the trust of doctors, patients and customers by providing a steady flow of innovative, science-based medicines and services that improve the health and well-being of people around the world.
  • Wyeth
    Wyeth pharmaceutical company brings health care products, medicines and vaccines that aim to improve lives and deliver value to customers.
  • Novartis
    Novartis is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and to enhance the quality of life.
  • GlaxoSmithKline
    Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
  • AstraZeneca
    One of the world's leading pharmaceutical companies providing effective prescription drugs and innovative prescription medicines in many important therapeutic areas.
  • Merck
    A global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.

Sponsor Links


My Online Status

Recent Comments

Healthcare

Sponsor Video

Archives

Subscribe to my Podcast

Blogroll

« [Research] Mediterranean Diet and Alzheimer Disease | Main | links for 2006-10-18 »

Millenium Pharmaceuticals (MLNM) Ends Its Bid For AnorMED (ANOR) , Leaving Genzyme (GENZ) On Top

Millenium Pharmaceuticals (MLNM) announced today that it will not increase its bid for Canadian biotech AnorMED (ANOR) following a bid by Genzyme (GENZ) for $13.50 a share.
Via: BioHealthInvestor
Via: Biotech SeekingAlpha

Genzyme started the jostling for AnorMED when it offered $8.50 a share. That bid was quickly rejected by AnorMED's board as it courted Millenium to step in and make an offer, which it did, at $13.

Genzyme reviewed Millenium's second offer and increased its own to the current $13.50.

Millenium's decision not to increase its offer a second time opens the door for other companies to take over AnorMED, if Genzyme's offer is not accepted.

Millenium also expects to recieve a payment of almost $20 million for breaking talks with AnorMED.

AnorMED's stem cell mobilizer Mozobil is at the heart of these takeover talks.

Posted at 09:16 PM in Rx Blog Biotechnology |

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341cce4453ef00d8356b715269e2

Listed below are links to weblogs that reference Millenium Pharmaceuticals (MLNM) Ends Its Bid For AnorMED (ANOR) , Leaving Genzyme (GENZ) On Top:

Comments

Verify your Comment

Previewing your Comment

Posted by:  | 

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.